Tedizolid: a new oxazolidinone antimicrobial. (Q34660917)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24688035%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

title

Tedizolid: a new oxazolidinone antimicrobial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24688035%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference

ChEBI release 2020-05-28

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24688035%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Nathan R Unger

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24688035%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

author name string

Jamie J Kisgen

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24688035%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Lindsey M Childs

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24688035%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

publication date

1 April 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24688035%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Health-System Pharmacy

12 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24688035%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

volume

71

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24688035%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24688035%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

page(s)

621-633

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24688035%20AND%20SRC:MED&resulttype=core&format=json

Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005

12 March 2020

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

Invasive methicillin-resistant Staphylococcus aureus infections in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

Health care-associated invasive MRSA infections, 2005-2008.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

Vancomycin-resistant enterococcal infections

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

Secular trends of hospitalization with vancomycin-resistant enterococcus infection in the United States, 2000-2006.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

Linezolid: an oxazolidinone antimicrobial agent

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

Linezolid resistance in a clinical isolate of Staphylococcus aureus

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

Oxazolidinones: activity, mode of action, and mechanism of resistance.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

Activity of tedizolid phosphate (TR-701) in murine models of infection with penicillin-resistant and penicillin-sensitive Streptococcus pneumoniae

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

In vitro activities of DA-7157 and DA-7218 against Mycobacterium tuberculosis and Nocardia brasiliensis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

Antimicrobial resistance to linezolid

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

In Vivo Pharmacodynamics of Torezolid Phosphate (TR-701), a New Oxazolidinone Antibiotic, against Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus Strains in a Mouse Thigh Infection Model

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

In vivo pharmacodynamics of a new oxazolidinone (linezolid)

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

Tedizolid (TR-701): a new oxazolidinone with enhanced potency

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

Antibiotics for skin infections: new study design and a step toward shorter course therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

Tigecycline-resistant Enterococcus faecalis strain isolated from a German intensive care unit patient

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130482

31 March 2020

Identifiers

DOI

10.2146/AJHP130482

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24688035%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference